Therapeutic stem cell nutrient composition and uses thereof

Abstract

The present invention relates to a composition and uses thereof for treatment of damaged tissue comprising at least one essential amino acid in L form and at least one essential lipid; wherein the composition is administered to a mammal suffering from severe tissue damage. The invention further relates to a composition and uses thereof comprising the mixture of one or more free L-amino acids in which the molar ratio of the free L-amino acids corresponds to the molar ratio of amino components in a mammalian tissue protein; and at least one essential lipid.

I claim: 
     
         1 . A method of treating damaged tissue comprising administering an anabolic composition to a mammal in need of such treatment, wherein the anabolic composition comprises: a) at least one extracellular matrix compound in an amount effective in the damaged tissue as anti-inflammatory and anti-angiogenic agent, b) at least one surfactant wherein the surfactant is selected from the group consisting of a lipid, a phospholipid, a glycolipid, a monoglyceride, a diglyceride, and lipoprotein; and c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of the amino acid composition of breast milk protein, and wherein no more than 10% of the amino acids are in D-form, and said gastrointestinal disease is Crohn's disease, ulcerative colitis or mucous colitis. 
     
     
         2 . The method of  claim 1 , wherein the surfactant is selected from the group consisting of a lipid, a phospholipid, a glycolipid, a monoglyceride, a diglyceride and lipoprotein. 
     
     
         3 . The method of  claim 1 , wherein the damaged tissue is selected from the group consisting of tissues of mesenchymal origin, tissues of endodermal origin, tissues of mesodermal origin and tissues of ectodermal origin. 
     
     
         4 . The method of  claim 1 , wherein the damaged tissue is selected from the group consisting of skin, eye, liver, gastro-intestinal, kidney, cardio-vascular system, respiratory tract, endocrine, joint, musculoskeletal system, peripheral nervous system, central nervous system and lung. 
     
     
         5 . The method of  claim 4 , wherein the damaged tissue is skin. 
     
     
         6 . The method of  claim 4 , wherein the gastro-intestinal tissue is bowel tissue. 
     
     
         7 . The method according to  claim 1 , wherein the anabolic composition comprises: a) at least one extracellular matrix compound selected from the group consisting of glucosamine, a glycosaminoglycan, a collagen, cartilage, chondroitin sulfate, hyaluronic acid, hyaluronan mucopolysaccharides, a glycoprotein, and a proteoglycan in an amount effective in the damaged tissue as anti-inflammatory and anti-angiogenic agent, b) at least one surfactant wherein the surfactant is selected from the group consisting of a lipid, a phospholipid, a glycolipid, a monoglyceride, a diglyceride, and lipoprotein; and c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of human breast milk protein, cyclosporin, penicillin, cephalosporin, sulfasalazine (azulfidine) or fibrinogen, and wherein no more than 10% of the amino acids are in D-form. 
     
     
         8 . The method according to  claim 7 , wherein the amino acids are present at a molar ratio which is characteristic of cyclosporin. 
     
     
         9 . The method according to  claim 7 , wherein the amino acids are present at a molar ratio which is characteristic of penicillin. 
     
     
         10 . The method according to  claim 7 , wherein the amino acids are present at a molar ratio which is characteristic of cephalosporin. 
     
     
         11 . The method according to  claim 7 , wherein the amino acids are present at a molar ratio which is characteristic of sulfasalazine (azulfidine). 
     
     
         12 . The method according to  claim 7 , wherein the amino acids are present at a molar ratio which is characteristic of fibrinogen. 
     
     
         13 . A composition for treating a damaged tissue, comprising: a) at least one mucopolysaccharide extracellular matrix compound in an amount effective in the damaged tissue as anti-inflammatory and anti-angiogenic agent, b) at least one surfactant; and c) a plurality of amino acids having an alpha carbon and wherein no more than 10% of the amino acids are in D-form. 
     
     
         14 . A composition for treating a damaged tissue, comprising: a) at least one mucopolysaccharide extracellular matrix compound in an amount effective in the damaged tissue as anti-inflammatory and anti-angiogenic agent, b) at least one surfactant; and c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of human breast milk or fibrinogen, wherein no more than 10% of the amino acids are in D-form. 
     
     
         15 . A method of treating HIV infection, comprising administering an anabolic composition according to  claim 14 .